$0.37-3.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
The quarter ending September 30, 2018, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2018 | 3 months toSep 30, 2017 | Change |
|---|---|---|---|
| Total Revenue | $55K | $56K | -1.79% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Tempest Therapeutics, Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“The third quarter marked a period of meaningful progress in the advancement of two next-generation in vivo CAR-T platforms with the potential to transform treatment across multiple diseases,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Tempest is a clinical-stage biotechnology company developing a pipeline of advanced in vivo CAR-T therapies designed to treat cancer and autoimmune disease by resetting dysfunctional immunity. Tempest’s portfolio includes TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate being evaluated in a Phase 1 study for relapsed or refractory multiple myeloma (rrMM). The Company’s lead lipid nanoparticle (LNP)-based in vivo CAR-T candidate, TPST-4003 combines a clinically supported dual-targeting CD19/BCMA CAR structure with an advanced CD7-targeting delivery platform to support broad immune reset across multiple indications. The company’s additional preclinical programs leverage advanced payloads to create a modular in vivo CAR-T portfolio. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need. For additional information, visit Tempest’s website at https://www.tempesttx.com. 3
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Tempest Therapeutics, Inc.’s Item 2.02 8-K filed November 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.